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Summary
Objective: TSG-6 [the product of tumor necrosis factor (TNF)-stimulated gene-6] is a hyaluronan-binding protein that is present in the
synovial fluids of arthritis patients and is secreted by cells of articular joints (e.g. chondrocytes and synoviocytes). This study examines the
pattern of TSG-6 expression in normal and diseased cartilage and synovium using immunohistochemical techniques.
Design: A polyclonal antibody was raised against recombinant Link module from human TSG-6 and used to detect the protein in tissue
sections taken from osteoarthritis (OA) and rheumatoid arthritis (RA) patients and controls.
Results: There was no TSG-6 detected in normal tissues. In all OA synovium there was intense TSG-6 expression throughout the intimal
layer, whereas in RA staining in this region was generally less pronounced and was absent at the synovial surface in tissues exhibiting
significant inflammation. In RA TSG-6 was also expressed by infiltrating leukocytes and by cells at the cartilage–synovium pannus junction.
TSG-6 immunoreactivity was present in the tunica intima of blood vessels in OA subintima, being particularly noticeable in the thickened
smooth muscle of inflamed vessel walls, but was mostly confined to the lumen of the vessel in RA. In cartilage the majority of chondrocytes
expressed TSG-6 in both OA and RA, usually with extensive staining in the surrounding matrix.
Conclusion: TSG-6 is present within synovium and cartilage of arthritic joints, but not normal controls, and is synthesized by the resident
cells. The pattern of TSG-6 expression is consistent with its proposed roles in extracellular matrix (ECM) remodeling and cellular proliferation.
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TSG-6 is a 35 kDa glycoprotein1 that is likely to have a
role in ECM remodeling, leukocyte migration and cell
proliferation.2–5 It is secreted by chondrocytes, fibroblasts,
monocytes and vascular smooth muscle cells (SMC) in
response to inflammatory mediators and growth factors,
but with little or no constitutive expression.1,4,6–9 Produc-
tion of TSG-6 is differentially regulated in these cell types.
For example, it is strongly induced in fibroblasts by
interleukin-1 (IL-1) and TNF, but not transforming growth
factor-1 (TGF-1)1,8,9, in monocytes by lipopolysaccha-
ride and TNF (but not IL-1),9 in SMC by IL-1 (but not
TNF), epidermal growth factor, fibroblast growth factor-1
and TGF-1,4 and in articular chondrocytes by IL-1, TNF,
platelet-derived growth factor AA and more weakly by42TGF-1, IL-6 and leukemia inhibitory factor.6 Further
details on TSG-6 expression, transcriptional regulation and
promoter structure can be found in an excellent review by
Wisniewski and Vilcek.10
TSG-6 protein has been found in the synovial fluids of
patients with rheumatoid arthritis (RA), osteoarthritis (OA),
Sjo¨gren’s syndrome, polyarthritic gout and osteomyelitis
but was not detected at autopsy in those from accident
victims without known joint disease.9 The highest levels of
TSG-6 were seen in RA, but similar amounts were found in
some patients with OA. The level of TSG-6 in serum was
considerably lower than that in the synovial fluids, indicat-
ing that it is produced locally within the affected joints,9
which is consistent with the in vitro expression studies
described above. In addition synoviocytes obtained from a
patient with RA were found to constitutively secrete TSG-6,
where the expression could be enhanced by IL-1 or TNF,
but not TGF-1. TSG-6 has been detected in proliferating
smooth muscle cells of arterial neointima following injury4
and is also expressed during fetal development.11
The human TSG-6 cDNA encodes a polypeptide of 277
amino acids including a 17-residue signal peptide.10 The
cartilage.
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REAGENTS, TISSUES AND PROTEIN EXPRESSION
Horseradish peroxidase (HRP)-conjugated immu-
noglobulins, protein A agarose, normal human serum and
general laboratory reagents were obtained from Sigma-
Aldrich, U.K. Biotinylated goat anti-rabbit immunoglobulin
and streptavidin-HRP were purchased from DAKO Ltd,
U.K. Hydrogen peroxide and DePex were from Merck Ltd,
U.K. The monoclonal antibody (mAb 8A4) to human carti-
lage link protein20,21 was a kind gift from Professor Bruce
Caterson, University of Wales, Cardiff.
Cartilage and synovium were obtained from patients with
OA (N=9) aged 52–82 years or RA (N=5) aged 53–88
years undergoing knee arthroplasty; the RA patients ful-
filled the revised criteria of the American College of Rheu-
matology.22 Control samples (N=4) aged 40–45 years
were from macroscopically normal knee joints of patients
undergoing above-knee amputation for osteosarcoma that
did not invade the joint. All tissue samples were from the
femoral condyle except in one OA patient where the carti-
lage, which included a region of osteophyte formation, wastaken from the proximal tibia. Tissues from the femoral
condyle were embedded in OCT resin (Tissue Tek, U.K.),
frozen in hexane/dry ice within 4 h of surgery and stored at
−70°C until required. The tibial plateau was fixed in forma-
lin, demineralized in HCl/EDTA (Surgipath Decalcifier II),
dehydrated and embedded in parafin.
The Link module from human TSG-6 (denoted Link
–
TSG6), corresponding to amino acids 36-133 in the prepro-
tein,1 was overexpressed as insoluble inclusion bodies in
E. coli as described in Day et al.15 The inclusion bodies
were isolated and correctly folded recombinant protein
purified as before;15,16 such material has been used
previously to determine the three-dimensional structure of
the Link module by nuclear magnetic resonance
spectroscopy.17 Link protein was prepared from human
21PREPARATION AND SPECIFICITY OF ANTI-TSG-6 ANTIBODY
A polyclonal antiserum was raised against the Link
module of human TSG-6. A rabbit was inoculated intra-
muscularly with protein preparation mixed to an emulsion
with an equal volume of Hunter’s TitreMax #R1 adjuvant
(CytRx Corporation, Norcross, GA, U.S.A.). Immunization
was initially carried out with the inclusion body preparation
(300 l total volume, containing approx. 1 g/l recom-
binant protein) followed by a booster injection on day 35
with purified, correctly folded TSG-6 Link module (0.5 g/l
in a total volume of 300 l). Sera were recovered prior to
immunization (pre-immune serum) and 41 days after the
second injection (anti-TSG6 antiserum).
Immunoglobulins were isolated from the antiserum using
Protein A agarose. Anti-TSG6 antibodies were further
purified by affinity chromatography on a 1 ml Hitrap
N-hydroxysuccinimide Sepharose column (Pharmacia Bio-
tech, U.K.) to which 0.82 mg of TSG-6 Link module had
been coupled according to manufacturer’s instructions. The
immunoglobulin preparation was applied to the column,
washed with the equilibrating buffer (0.1 M Tris, pH 8.0)
and bound material eluted with 0.1 M glycine-HCl, pH 2.4.
Fractions containing protein (adjusted to pH 8 with 1 M Tris
pH 9.0) were pooled and exchanged into PBS using a
Centricon 10 microconcentrator (Amicon, MA, U.S.A.) to
give a final concentration of about 1 g/ml and stored in
aliquotes at −20°C.
The specificity and cross-reactivity of the anti-TSG-6
antiserum was assessed by Western blot analysis as
follows. The TSG-6 Link module (2 g/lane) and cartilage
link protein (1 g/lane) were run under reducing conditions
on 10% (w/v) Tris-tricine sodium dodecyl sulfate-
polyacrylamide gels23 and electro-blotted onto Immobilon
polyvinylidene difluoride membranes (Millipore, U.K.).
Washes were performed in phosphate buffered saline
(PBS) after each stage of the procedure, all of which were
carried out at room temperature. The membranes were
blocked [for 1 h in 5% (w/v) milk powder in PBS] and
washed thoroughly. They were then incubated with a
1:1000 dilution of primary antibody (anti-TSG6 or mAb 8A4)
and, following washing, with a 1:5000 dilution of the HRP-
conjugated secondary antibody (polyclonal IgG: goat anti-
rabbit or goat anti-mouse, respectively) for 1 h each in 1%
(w/v) milk powder in PBS. A 1:1000 dilution of the pre-
immune serum was used as a negative control. After a
final wash, antibody binding was visualized by the
enhanced chemiluminescence system, according to the
instructions of the supplier (Amersham, U.K.). The cross-
reactivity of the TSG-6 antiserum was also tested againstmature protein is comprised of a Link module (generally
found in hyaluronan-binding proteins12) and a CUB mod-
ule,13,14 arranged contiguously, with short peptides at the
N- and C-termini (18 and 29 amino acids, respectively).
The Link module from human TSG-6, produced by recom-
binant expression in bacteria,15,16 has been shown to
interact specifically with hyaluronan, chondroitin-4-sulphate
and the proteoglycan aggrecan.5,17,18 As these ligands are
all components of ECM, it is likely that TSG-6 has a role in
matrix remodeling during inflammation, wound healing and
development. In this regard we have previously hypoth-
esized that TSG-6 could compete with aggrecan for the
interaction of HA and thereby inhibit the formation of
cartilage aggregates (huge multimolecular complexes
which provide cartilage with its load bearing properties), or
even dissociate them.5 TSG-6 also forms a covalent com-
plex with the inter--inhibitor (II), a serine protease inhibi-
tor, and thereby increases its anti-plasmin activity.2,19 This
suggests a role for TSG-6 in the regulation of the plasmin/
plasminogen activator system and, therefore, the control of
growth factor and matrix metalloproteinase activation.10
TSG-6 has been shown to be a potent inhibitor of neutrophil
migration in vivo in a murine air pouch model of
carrageenan- or IL-1-induced acute inflammation.2 This
could be either receptor-mediated or be due to down-
regulation of protease activity. In addition TSG-6 has been
demonstrated to stimulate vascular SMC proliferation.4
TSG-6 expression appears to be tightly regulated and it
is likely that this protein is important in ECM remodeling,
but at present it is not clear whether it has a stabilizing or
dissociative role (or both). Although previous studies
strongly suggest that TSG-6 is produced by cells of articu-
lar joints during arthritic diseases6,9 its expression pattern
within joint tissues themselves has not been investigated
directly; this information is essential if we are to begin to
understand TSG-6 function. Therefore, we have generated
an antibody against human TSG-6 that has allowed the
localization of this protein in synovium and cartilage from
OA and RA patients compared to controls. This study
shows that TSG-6 is produced within synovium and carti-
lage in OA and RA, with little or no expression in normal
tissues.
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for link protein.U.K.).ResultsCHARACTERIZATION AND PURIFICATION OF ANTI-TSG6 ANTIBODIES
A rabbit polyclonal antibody was raised against the Link
module of human TSG-6 (Link
–
TSG6), a 10.9 kDa recom-
binant domain expressed in E. coli.15,16 The specificity and
cross-reactivity of the antiserum was investigated by West-
ern blot analysis (see Fig. 1). The anti-TSG6 antiserum
recognized the immunogen, but did not cross-react with
human link protein (which contains two Link module
domains with 33.7 and 32.3% sequence identity, respect-
ively, to Link
–
TSG6).17 There was no immunoreactivity to
Link
–
TSG6 (or link protein) in the pre-immune serum (data
not shown). The presence of link protein (LP1 and LP2) on
the blot was confirmed using mAb 8A4 and this antibody
did not bind to Link
–
TSG6 (Fig. 1).
Preliminary immunohistochemical studies with the anti-
TSG6 antiserum and pre-immune serum gave rise to high
non-specific background, which was absent in controls
containing secondary antibody only. Therefore, anti-TSG6specific antibodies were isolated from the antiserum by
affinity chromatography on Link
–
TSG6-Sepharose (see
above). The purified antibody preparation was found to
have the same specificity as the antiserum on Western
blots (data not shown) but gave considerably lower back-
ground staining on tissue sections. Therefore, the purified
anti-TSG6 antibody was used in all subsequent immunolo-
calization experiments (see below). TSG-6 immunostaining
was performed on synovium and cartilage from patients
with OA or RA and on control tissue from macroscopically
normal joints.Fig. 1. Determination of the specificity of anti-TSG6 antiserum by
Western analysis. Blots containing recombinant Link module from
human TSG-6 (Link
–
TSG6) and link protein (LP) purified from
human cartilage were probed with either anti-TSG6 antiserum (left
panel) or mAb 8A4 (right panel). The anti-TSG6 antiserum could
detect the 10.9 kDa Link
–
TSG6 (the immunogen) but did not
cross-react with any species in the link protein preparation,
whereas, mAb 8A4 recognized link protein-1 (LP1) and -2 (LP2);
the faint bands seen between 26–30 kDa probably correspond to
the link protein fragments described previously.21 Molecular
weights indicated are based on Rainbow size markers (Amersham,TSG-6 EXPRESSION IN SYNOVIUM
Eight samples of OA synovium were studied (five fibrous,
three areolar) and compared with normal controls (N=2).
TSG-6 was detected in all OA samples, whereas there was
very little or no immunoreactivity in the normal tissues.
There was no staining in the absence of primary antibody in
these or any other tissues tested. As can be seen from Fig.
2(a) (which shows a typical micrograph for OA synovium)
staining is particularly intense (and continuous) throughout
the intimal layer. For this reason it is not possible to tell if
TSG-6 is being expressed by an individual population of
synoviocytes (i.e. type A or B) or by all intimal cells. TSG-6
was also detectable within the subintima where, in some
instances, it was localized in the cytoplasm of fibroblasts
with extended cellular processes (not shown).
TSG-6 immunoreactivity was also present in RA syn-
ovium (one areolar and three fibrous). Its distribution in
three of these was different to that found in OA, with very
little TSG-6 detected at the synovial surface and some
discontinuous staining within the intima and subintima; thisIMMUNOHISTOCHEMISTRY
Frozen sections (5 m) were air-dried and fixed in cold
acetone. All subsequent washes, incubations and dilutions
were performed at room temperature in PBS, except where
indicated otherwise. Endogenous peroxidase activity was
blocked by treatment with 1% (v/v) hydrogen peroxide in
methanol for 10 min. The sections were treated for 1 h with
a 1 in 20 dilution of the affinity-purified anti-TSG6 antibody
(or with PBS alone as a control) and washed twice.
Sections were then incubated with biotinylated-goat anti-
rabbit immunoglobulin (1:50), washed as before, followed
by streptavidin-conjugated HRP (1:100) and washed again;
these incubations were carried out for 30 min in reagents
diluted in 20% (v/v) normal human serum (in PBS) to block
non-specific binding. Color was developed using Sigma
Fast 3,3-diaminobenzidine (DAB) tablet sets (Sigma-
Aldrich, U.K.) according to the manufacturer’s instructions,
and then rinsed with tap water. Slides were counterstained
with hemotoxylin, dehydrated in alcohol, cleared with
Histo-clear and mounted in DePex.
Paraffin-embedded sections (5 m) were deparaffinized
with xylene and rehydrated through a series of graded
alcohols. All incubations and washes in TBS (0.05 M Tris,
0.15 M NaCl pH 7.6) were carried out at room temperature
unless indicated otherwise. Sections were incubated with
0.3% (v/v) hydrogen peroxide in methanol for 15 min,
washed with distilled water followed by TBS and treated
with 40 mU/ml chondroitinase ABC (Seikagaku America
Inc.) in 0.1 M Tris/acetate pH 7.6, containing 1% (w/v)
bovine serum albumin (BSA), at 37°C. They were then
washed, blocked with 10% (v/v) normal goat serum for 1 h
at room temperature, incubated with the affinity purified
anti-TSG6 antibody (diluted 1 in 20 as above) in TBS
containing 1% (w/v) BSA for 1 h and washed extensively.
Bound antibody was detected using biotinylated-goat anti-
rabbit secondary antibody and the Histomark streptavidin-
HRP system with DAB substrate (Kirkegaard & Perry
Laboratories Inc.) as recommended by the supplier. The
sections were counterstained and mounted as described
above.
Osteoarthritis and Cartilage Vol. 9 No. 1 45Fig. 2. Immunolocalization of TSG-6 in synovium and cartilage from arthritis patients. Frozen (a–d) or paraffin-embedded (e, f) sections were
incubated with an affinity-purified anti-TSG6 antibody and localized using the immunoperoxidase method (brown stain), followed by
hematoxylin counterstaining as described in Materials and methods. (a) OA fibrous synovium showing intimal (I) and subintimal (SI) regions.
(b) RA fibrous synovium with chronic hyperplasia (BV, blood vessel). (c) OA fibrous synovium with inflamed blood vessels. (d) RA
cartilage–synovial pannus junction [SCJ, synovial (S) cartilage (C) junction]. (e) OA cartilage showing the cartilage surface (CS), calcified
cartilage (CC) and bone (B). (f) OA cartilage overlying a region of osteophyte formation. Original magnifications ×40 (e, f), ×125 (a–c) or
×250 (d).is illustrated in Fig. 2(b) in a sample exhibiting chronic
hyperplasia. In the other RA sample (which was the least
inflamed) there was significant TSG-6 expression in the
intimal layer, which had a morphology and staining pattern
similar to those seen in OA (not shown). In all the RA
samples individual TSG-6 positive cells which are likely to
be infiltrating leukocytes, although the identification of
these cells was not performed using leukocyte markers,
were scattered throughout the synovium [see Fig. 2(b)].
There was no detectable TSG-6 in lymphoid aggregates
present in either the RA or OA samples.Expression of TSG-6 was seen in all blood vessels of RA
and OA synovium. In the RA sections, TSG-6 was mainly
confined to the innermost lining of the vessel [see Fig.
2(b)], but was also detected within the striated smooth
muscle (where apparent) of the vessel walls. In the OA
samples TSG-6 was present throughout the tunica intima.
Two of the fibrous OA specimens (with vascularization and
thickening of the vascular smooth muscle consistent with
chronic inflammation) had continuous TSG-6 staining
within the tunica media, tunica adventitia and extending
into the interstitium [see Fig. 2(c)].
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pannus [see Fig. 2(d)]. At the cartilage–synovial junction all
cells (many of which did not have morphological features
typical of chondrocytes or synoviocytes) had detectable
TSG-6. The expression was most intense at the junction of
the two tissues and there were also some regions of
extracellular staining.TSG-6 EXPRESSION IN CARTILAGE
All sections of cartilage from individuals with RA (N=4)
and OA (N=7) had a high proportion (approximately 80%)
of chondrocytes that were expressing TSG-6, particularly in
the mid and deep zones of the tissue. In the RA and five of
the OA specimens there was pericellular and territorial
ECM staining; TSG-6 was also detectable in some inter-
territorial regions and staining was generally more intense
in the OA samples. This is illustrated in Fig. 2(e) for eroded
OA cartilage from the proximal tibia. Cartilage from a site of
osteophyte formation was also taken from the same patient
and showed a somewhat different TSG-6 staining pattern
[see Fig. 2(f)]. In this case TSG-6 was more specifically
localized to the mid and deep zones, with extensive ECM
staining associated with chondrocytes in regions undergo-
ing mineralization. There was also staining in the blood
vessels of the newly calcified cartilage layer.Discussion
Here we establish that TSG-6 is expressed within the
joint tissues of arthritis patients and, therefore, these are
likely to be the source of TSG-6 protein detected in synovial
fluids.6,9 No TSG-6 immunostaining was observed in nor-
mal tissues, but there was marked up-regulation in sections
obtained from patients suffering from OA and RA.
TSG-6 has been hypothesized to have a number of
important biological roles, including remodeling of ECM,
regulation of leukocyte migration and stimulation of cell
proliferation, during inflammation and wound heal-
ing.4,5,10,12,18 The localization of the protein at sites in
cartilage and within inflamed synovium (in and around
blood vessel structures) and its expression by infiltrating
leukocytes are consistent with these functions.
Ye et al.4 showed that vascular SMC that are made to
constitutively express TSG-6 proliferate at a considerably
faster rate than non-expressing cells. In addition, prolifer-
ating SMC of the neointima, which forms following blood
vessel injury, stained positive for TSG-6, whereas there
was little or no TSG-6 detected in non-ballooned arteries.4
In this context it is interesting that we observed consider-
able deposition of TSG-6 in blood vessel walls and in the
synovial intima from arthritis patients. We have also
detected the protein within the pannus region of synovium
that was invading rheumatoid cartilage. The staining pat-
tern is consistent with TSG-6 having effects on cell prolifer-
ation and this could be mediated in a number of ways, for
example, by TSG-6 either acting directly as a growth factor
or indirectly by modulation of cell-ECM contacts.
It was shown previously that the Link module of TSG-6
binds with high affinity to the 4-sulfated, but not the
6-sulfated isomer of chondroitin sulfate.18 This is interest-
ing as normal adult cartilage contains primarily chondroitin-
6-sulphate (C6S)24 and there is evidence of an increase in
the synthesis of chondroitin-4-sulfate (C4S) in disease. For
example, IL-1 (which stimulates TSG-6 expression inchondrocytes)6,7 significantly increases the level of C4S
(measured as total disaccharide released following enzy-
matic digestion) produced in chondrocytes while reducing
the synthesis of C6S.25 Another study indicates that there
are increased levels of C4S on the glycosaminoglycan
chains of proteoglycans (including aggrecan), in articular
cartilage from OA patients.26 Differences in C6S and C4S
localization in normal and diseased synovium have also
been observed;27 C4S was found to be distributed evenly
throughout the interstitium in normal human synovium;
however, in RA C4S occurs at reduced levels in the matrix
and becomes localized to blood vessel walls. As noted
previously, some caution is needed when interpreting these
later studies as they both used monoclonal antibodies that
only recognize the disaccharide ‘stub’ that is left on the
proteoglycan following chondroitinase treatment and,
therefore, do not necessarily represent changes in the
glycosaminoglycan chains as a whole.24,28 It is clear,
however, that disease associated changes in C4S distribu-
tion in cartilage and synovium are likely to affect the
localization and, thus, the biological role of TSG-6.
The hypothesis that TSG-6 is involved in the stability of
proteoglycan aggregates is an appealing one and is sup-
ported by our findings that TSG-6 is localized in the regions
of osteoarthritic and osteophytic cartilage remodeling. In
this respect, TSG-6 expression by chondrocytes is upregu-
lated by TGF-1 which is known to be present in high
concentrations in remodeling tissues.6 The Link module of
TSG-6 can bind directly to the G1 domain of aggrecan in
vitro and may, thus, inhibit the interaction of aggrecan with
hyaluronan to form multimolecular aggregates.5 It is also
possible that TSG-6 could have a role in cross-linking
components of the ECM via its Link module and its CUB
module. In this regard, CUB modules in other proteins have
been found to bind to collagen-like structures, members of
the TGF- superfamily and glycosaminoglycans.13,14,29
TSG-6 forms a covalent complex with II19 and this has
been detected in the synovial fluid of patients with various
forms of arthritis,9 albeit at low levels compared to TSG-6
alone. This complex (II/TSG-6) has been demonstrated
to inhibit the plasmin/plasminogen activator system.2
Therefore, it is likely to regulate the activation of TGF-1
and matrix metalloproteinases, thus having an anti-
inflammatory effect.10 It is not known if the II/TSG-6
complex is present in articular cartilage and synovium, but
II immunoreactivity has recently been observed in the
growth plate and it was also reported that osteoprogenitor
cells and hypertrophic chondrocytes have hyaluronan and
II on their surfaces.30 At present it is unclear whether the
II/TSG-6 complex plays any role in remodeling of joint
tissue matrices, but it is interesting to note that differential
expression of components of the plasminogen activation
system has been seen in the synovial tissues of patients
with RA and OA.31 II is itself an hyaluronan-binding
protein and, therefore, it is possible that the II/TSG-6
complex, if present, could mediate the cross-linking of
separate HA chains and thus act to stabilize ECM.3
The synthesis of TSG-6 by human joint tissues and the
differential distribution of this protein in arthritic conditions
described here provides further evidence for its important
role in extracellular matrix remodeling.Acknowledgments
We wish to thank the Arthritis Research Campaign U.K. for
their financial support and Selina Blades for technical
Osteoarthritis and Cartilage Vol. 9 No. 1 47assistance, Stephen Lee for his help in preparing the
figures and Dr Caroline Milner for critical review of the
manuscript.References
1. Lee TH, Wisniewski HG, Vilcek J. A novel secretory
tumor necrosis factor-inducible protein (TSG-6) is a
member of the family of hyaluronate binding proteins,
closely related to the adhesion receptor CD44. J Cell
Biol 1992;116:545–57.
2. Wisniewshki HG, Hua JC, Poppers DM, Naime D,
Vilcek J, Cronstein BN. TNF/IL-1-inducible protein
potentiates plasmin inhibition by inter--inhibitor and
exerts a strong anti-inflammatory effect. J Immunol
1996;156:1609–15.
3. Fu¨lo¨p C, Kamath RV, Li Y, Otto JM, Salustri A, Olsen
BR, et al. Coding sequence, exon-intron structure
and chromosomal localization of murine TNF-
stimulated gene 6 that is specifically expressed by
expanding cumulus cell-oocyte complexes. Gene
1997;202:95–102.
4. Ye L, Mora R, Akhayani N, Haudenschild CC, Liau G.
Growth factor and cytokine-regulated hyaluronan-
binding protein TSG-6 is localized to the injury-
induced rat neointima and confers enhanced growth
in vascular smooth muscle cells. Circ Res
1997;81:289–96.
5. Parkar AA, Kahmann JD, Howat SLT, Bayliss MT, Day
AJ. TSG-6 interacts with hyaluronan and aggrecan in
a pH-dependent manner via a common functional
element: implications for its regulation in inflamed
cartilage. FEBS Lett 1998;428:171–6.
6. Maier R, Wisniewski HG, Vilcek J, Lotz M. TSG-6
expression in human articular chondrocytes: possible
implications in joint inflammation and cartilage deg-
radation. Arthritis Rheum 1996;39:552–9.
7. Margerie D, Flechtenmacher J, Bu¨ttner FN, Karbowski
A, Wolfhart P, Schleyerbach R, et al. Complexity of
IL-1 induced gene expression pattern in human
articular chondrocytes. Osteoarthritis Cart
1997;5:129–38.
8. Lee TH, Klampfer L, Shows TB, Vilcek J. Transcrip-
tional regulation of TSG-6, a tumor necrosis factor-
and interleukin-1-inducible primary response gene
coding for a secreted hyaluronan-binding protein. J
Biol Chem 1993;268:6154–60.
9. Wisniewski HG, Maier R, Lotz M, Lee S, Klampfer L,
Lee TH, et al. TSG-6: a TNF-, IL-1, and LPS-
inducible secreted glycoprotein associated with
arthritis. J Immunol 1993;151:6593–601.
10. Wisniewski HG, Vilcek J. TSG-6: an IL-1/TNF-
inducible protein with an anti-inflammatory activity.
Cytokine Growth Factor Rev 1997;8:143–56.
11. Feng P, Liau G. Identification of a novel serum and
growth factor-inducible gene in vascular smooth
muscle cells. J Biol Chem 1993;268:9387–92.
12. Day AJ. The structure and regulation of hyaluronan-
binding proteins. Biochem Soc Trans 1999;27:115–
21.
13. Bork P, Beckmann G. The CUB domain: a widespread
module in developmentally proteins. J Mol Biol
1993;231:539–45.
14. Day AJ, Barlow PN, Steinkasserer A, Campbell ID, Sim
RB. Progress in determining module structures in
C1r and C1s. Behring Inst Mitt 1993;93:31–40.15. Day AJ, Aplin RT, Willis AC. Overexpression, purifica-
tion, and refolding of link module from human
TSG-6 in Escherichia coli: effect of temperature,
media, and mutagenesis on lysine misincorporation
at arginine AGA codons. Protein Express Purif
1996;8:1–16.
16. Kahmann JD, Koruth R, Day AJ. Method for quantita-
tive refolding of the Link module from human TSG-6.
Protein Express Purif 1997;9:315–18.
17. Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki
FM, Campbell ID, et al. Solution structure of the Link
module: a hyaluronan-binding domain involved in
extracellular matrix stability and cell migration. Cell
1996;86:767–75.
18. Parkar AA, Day AJ. Overlapping sites on the Link
module of human TSG-6 mediate binding to hyaluro-
nan and chondroitin-4-sulphate. FEBS Lett
1997;410:413–17.
19. Wisniewski HG, Burgess WH, Oppenheim JD, Vilcek
J. TSG-6, an arthritis-associated hyaluronan binding
protein, forms a stable complex with the serum
protein inter--inhibitor. Biochem 1994;33:7423–9.
20. Caterson B, Baker JR, Christner JE, Lee Y, Lentz M.
Monoclonal antibodies as probes for determining the
microheterogeneity of the link proteins of cartilage
proteoglycan. J Biol Chem 1985;260:11348–56.
21. Mort JS, Caterson B, Poole AR, Roughley PJ. The
origin of human cartilage link protein heterogeneity
and fragmentation during ageing. Biochem J
1985;232:805–12.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ,
Fries JF, Cooper NS, et al. The American Rheuma-
tism Association 1987 revised criteria for the classifi-
cation of rheumatoid arthritis. Arthritis Rheum
1988;31:315–24.
23. Schagger H, von Jagow G. Tricine-sodium dodecyl
sulfate-polyacrylamide gel electrophoresis for the
separation of proteins in the range from 1 to 100 kDa.
Anal Biochem 1987;166:368–79.
24. Bayliss MT, Osborne D, Woodhouse S, Davidson C.
Sulfation of chondroitin sulfate in human articular
cartilage: the effect of age, topographical position,
and zone of cartilage on tissue composition. J Biol
Chem 1999;274:15892–900.
25. Shingu M, Miyauchi S, Nagai Y, Yasutake C, Horie K.
The role of IL-4 and IL-6 in IL-1-dependent cartilage
matrix degradation. Br J Rheumatol 1995;34:101–6.
26. Cs-Szabo G, Roughley PJ, Plaas AHK, Glant TT.
Large and small proteoglycans of osteoarthritic and
rheumatoid articular cartilage. Arthritis Rheum
1995;38:660–8.
27. Worrall JG, Wilkinson LS, Bayliss MT, Edwards JCW.
Zonal distribution of chondroitin-4-sulphate/dermatan
sulphate and chondroitin-6-sulphate in normal and
diseased human synovium. Ann Rheum Dis
1994;53:35–8.
28. Plaas AHK, Wong-Palms S, Roughley PJ, Midura RJ,
Hascall VC. Chemical and immunological assay of
the nonreducing terminal residues of chondroitin sul-
fate from human aggrecan. J Biol Chem
1997;272:20603–10.
29. Solis D, Romero A, Jimenez M, Diaz-Maurino T, Cal-
vete JJ. Binding of mannose-6-phosphate and
heparin by boar seminal plasma PSP-II, a member of
the spermadhesin protein family. FEBS Lett
1998;431:273–8.
48 M. T. Bayliss et al.: TSG-6 in human cartilage and synovium30. Kobayashi H, Sun GW, Terao T. Immunolocalization of
hyaluronic acid and inter-alpha-trypsin inhibitor in
mice. Cell Tissue Res 1999;296:587–97.
31. Ronday HK, Smits HH, van Muijen GNP, Pruszczynski
MSM, Dolhain RJEM, van Langelaan EJ, et al. Dif-ference in expression of the plasminogen activation
system in synovial tissue of patients with rheumatoid
arthritis and osteoarthritis. Br J Rheumatol
1996;35:416–23.
